Small nuclear ribonucleoprotein associated polypeptide N accelerates cell proliferation in pancreatic adenocarcinoma

Ma,Jin; Zhang,Zhuo; Wang,Jiancheng

doi:10.3892/mmr.2015.4208

Small nuclear ribonucleoprotein associated polypeptide N accelerates cell proliferation in pancreatic adenocarcinoma

Authors:
- Jin Ma
- Zhuo Zhang
- Jiancheng Wang
View Affiliations

Affiliations: Department of Gastroenterology, The Affiliated Ruijin Hospital Lu Wan Branch of Medical College, Shanghai Jiao Tong University, Shanghai 200020, P.R. China, Department of General Surgery, The Affiliated Ruijin Hospital of Medical College, Shanghai Jiao Tong University, Shanghai 200025, P.R. China
Published online on: August 11, 2015 https://doi.org/10.3892/mmr.2015.4208
Pages: 6060-6064

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The spliceosome, the large RNA‑protein molecular complex, is crucial for pre‑mRNA splicing. Several antitumor drugs have been found to tightly bind to the components of the spliceosome and mutations in the spliceosome have been reported in several types of cancer. However, the involvement of the spliceosome in pancreatic adenocarcinoma remains unclear. In the present study, small nuclear ribonucleoprotein associated polypeptide N (SNRPN), a key constituent of spliceosomes, was disrupted in BxPC‑3 pancreatic adenocarcinoma cells using lentivirus‑mediated RNA interference (RNAi). It was found that knockdown of SNRPN reduced the proliferation ability of BxPC‑3 cells, as determined by an MTT assay. Furthermore, cell colony formation was impaired in SNRPN depleted adenocarcinoma cells and cell cycle analysis showed that depletion of SNRPN led to S phase cell cycle arrest and apoptosis. These results suggest that SNRPN is a key player in pancreatic adenocarcinoma cell growth, and targeted loss of SNRPN may be a potential therapeutic method for pancreatic cancer.

View Figures

View References

1	Hariharan D, Saied A and Kocher HM: Analysis of mortality rates for pancreatic cancer across the world. HPB (Oxford). 10:58–62. 2008. View Article : Google Scholar
2	Decker GA, Batheja MJ, Collins JM, et al: Risk factors for pancreatic adenocarcinoma and prospects for screening. Gastroenterol Hepatol (NY). 6:246–254. 2010.
3	Shain AH, Giacomini CP, Matsukuma K, et al: Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proc Natl Acad Sci USA. 109:E252–E259. 2012. View Article : Google Scholar : PubMed/NCBI
4	Jones S, Zhang X, Parsons DW, et al: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 321:1801–1806. 2008. View Article : Google Scholar : PubMed/NCBI
5	Efthimiou E, Crnogorac-Jurcevic T, Lemoine NR and Brentnall TA: Inherited predisposition to pancreatic cancer. Gut. 48:143–147. 2001. View Article : Google Scholar : PubMed/NCBI
6	Chang H: RNAi-mediated knockdown of target genes: a promising strategy for pancreatic cancer research. Cancer Gene Ther. 14:677–685. 2007. View Article : Google Scholar : PubMed/NCBI
7	Gartel AL and Kandel ES: RNA interference in cancer. Biomol Eng. 23:17–34. 2006. View Article : Google Scholar : PubMed/NCBI
8	Okamoto K and Murawaki Y: The therapeutic potential of RNA interference: novel approaches for cancer treatment. Curr Pharm Biotechnol. 13:2235–2247. 2012. View Article : Google Scholar
9	Zhao X, Zhu DM, Gan WJ, et al: Lentivirus-mediated shRNA interference targeting vascular endothelial growth factor inhibits angiogenesis and progression of human pancreatic carcinoma. Oncol Rep. 29:1019–1026. 2013.
10	Zhu XY, Liu N, Liu W, Song SW and Guo KJ: Silencing of the integrin-linked kinase gene suppresses the proliferation, migration and invasion of pancreatic cancer cells (Panc-1). Genet Mol Biol. 35:538–544. 2012. View Article : Google Scholar : PubMed/NCBI
11	Li C, Ge M, Yin Y, Luo M and Chen D: Silencing expression of ribosomal protein L26 and L29 by RNA interfering inhibits proliferation of human pancreatic cancer PANC-1 cells. Mol Cell Biochem. 370:127–139. 2012. View Article : Google Scholar : PubMed/NCBI
12	Hoskins AA and Moore MJ: The spliceosome: a flexible, reversible macromolecular machine. Trends Biochem Sci. 37:179–188. 2012. View Article : Google Scholar : PubMed/NCBI
13	Will CL and Luhrmann R: Spliceosome structure and function. Cold Spring Harb Perspect Biol. 3:pii2011. View Article : Google Scholar
14	Wahl MC, Will CL and Lührmann R: The spliceosome: design principles of a dynamic RNP machine. Cell. 136:701–718. 2009. View Article : Google Scholar : PubMed/NCBI
15	Chesnais V, Kosmider O, Damm F, et al: Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia. Oncotarget. 3:1284–1293. 2012. View Article : Google Scholar
16	Scott LM and Rebel VI: Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors. J Natl Cancer Inst. 105:1540–1549. 2013. View Article : Google Scholar : PubMed/NCBI
17	Bonnal S, Vigevani L and Valcárcel J: The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov. 11:847–859. 2012. View Article : Google Scholar : PubMed/NCBI
18	Cappellari M, Bielli P, Paronetto MP, et al: The transcriptional co-activator SND1 is a novel regulator of alternative splicing in prostate cancer cells. Oncogene. 33:3794–3802. 2014. View Article : Google Scholar
19	Quidville V, Alsafadi S, Goubar A, et al: Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy. Cancer Res. 73:2247–2258. 2013. View Article : Google Scholar : PubMed/NCBI
20	Lee SH, Appleby V, Jeyapalan JN, et al: Variable methylation of the imprinted gene, SNRPN, supports a relationship between intra-cranial germ cell tumours and neural stem cells. J Neurooncol. 101:419–428. 2011. View Article : Google Scholar
21	Benetatos L, Hatzimichael E, Dasoula A, et al: CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes. Leuk Res. 34:148–153. 2010. View Article : Google Scholar
22	McGarrity GJ, Hoyah G, Winemiller A, et al: Patient monitoring and follow-up in lentiviral clinical trials. J Gene Med. 15:78–82. 2013. View Article : Google Scholar : PubMed/NCBI
23	D'Costa J, Mansfield SG and Humeau LM: Lentiviral vectors in clinical trials: Current status. Curr Opin Mol Ther. 11:554–564. 2009.PubMed/NCBI
24	Fallini C, Bassell GJ and Rossoll W: Spinal muscular atrophy: the role of SMN in axonal mRNA regulation. Brain Res. 1462:81–92. 2012. View Article : Google Scholar : PubMed/NCBI